Clovis Oncology, Inc. announced updated data from the Phase 2 TRION2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, which is held in Spain Sept 27 through Oct 1.
The data shows a 43.9% confirmed objective response rate (ORR) in 57 RECIST*-evaluable patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1/2 mutation, as well as a 52.0% confirmed prostate-specific antigen (PSA) response in 98 PSA-evaluable patients with mCRPC and a BRCA1/2 mutation.
The TRITON2 data will be used to support the filing of Clovis Oncology’s planned supplemental NDA to the Food and Drug Administration (FDA) for Rubraca in BRCA1/2-mutant advanced prostate cancer.
“The updated data from the TRITON2 trial confirm the potential role of rucaparib in treating metastatic castration-resistant prostate cancer,” said Wassim Abida, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center, and principal investigator for the TRITON2 study. “These data specifically demonstrate the efficacy of rucaparib in eligible mCRPC patients with a BRCA1/2 mutation and reinforce the known safety profile in this treatment setting, showing it has the potential to offer clinical benefit to eligible patients.”
Wassim Abida, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center, and principal investigator for the TRITON2 study
Call to Action: Interested in learning more about the progress and development of Rubraca? Sign up for our newsletter.Source: Business Wire